4D Molecular announced FDA clearance of the investigational new drug application, or IND, for 4D-150, an R100 vector-based intravitreal genetic medicine, for the treatment of patients with Diabetic Macular Edema, or DME.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FDMT:
- 4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema
- 4D Molecular initiated with an Outperform at BMO Capital
- 4D Molecular provides update on Fabry Disease Cardiomyopathy
- 4D Molecular announces updates on clinical pipeline
- 4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs
